BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105 at Leerink Partners
October 30, 2024 6:26 AM EDTLeerink Partners analyst Joseph Schwartz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $105.00 (from $132.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This time last year on the 3Q23 earnings conference call, former CEO Jean Jacques (JJ) Bienaimé publicized his retirement (effective December 1, 2023) and Alexander Hardy who was the CEO of Genentech at Roche (RHHBY, Not Rated) at... More
